FINAZZI, MARIA CHIARA
 Distribuzione geografica
Continente #
EU - Europa 2.981
NA - Nord America 2.187
AS - Asia 2.092
SA - Sud America 205
AF - Africa 50
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.542
Nazione #
US - Stati Uniti d'America 2.095
DE - Germania 1.253
IT - Italia 595
CN - Cina 578
SG - Singapore 498
JP - Giappone 270
GB - Regno Unito 262
BD - Bangladesh 185
BR - Brasile 131
RU - Federazione Russa 127
VN - Vietnam 127
FR - Francia 117
HK - Hong Kong 110
IN - India 104
NL - Olanda 95
SE - Svezia 85
ES - Italia 78
IE - Irlanda 69
CA - Canada 52
FI - Finlandia 49
PL - Polonia 49
ID - Indonesia 42
CH - Svizzera 35
AT - Austria 32
KR - Corea 30
TW - Taiwan 30
DK - Danimarca 29
TR - Turchia 24
AR - Argentina 21
MX - Messico 21
CO - Colombia 19
AU - Australia 17
SA - Arabia Saudita 17
CL - Cile 16
UA - Ucraina 14
CI - Costa d'Avorio 13
GR - Grecia 13
TH - Thailandia 13
RS - Serbia 12
HR - Croazia 11
IL - Israele 11
BE - Belgio 10
NZ - Nuova Zelanda 9
CZ - Repubblica Ceca 8
EG - Egitto 8
MA - Marocco 8
PH - Filippine 8
IQ - Iraq 7
SI - Slovenia 7
EC - Ecuador 6
PT - Portogallo 6
RO - Romania 6
ZA - Sudafrica 6
BG - Bulgaria 5
HN - Honduras 5
IM - Isola di Man 5
IR - Iran 5
MY - Malesia 5
JM - Giamaica 4
UY - Uruguay 4
GT - Guatemala 3
KZ - Kazakistan 3
SC - Seychelles 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
DZ - Algeria 2
GE - Georgia 2
KE - Kenya 2
KH - Cambogia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
UG - Uganda 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
SD - Sudan 1
Totale 7.539
Città #
Frankfurt am Main 1.091
Singapore 271
Ashburn 215
Southend 162
Milan 151
Dallas 139
Chandler 129
San Jose 110
Beijing 109
Hong Kong 98
Fairfield 84
Santa Clara 74
Dublin 68
Tokyo 62
New York 60
Los Angeles 54
Princeton 54
Council Bluffs 53
Seattle 52
Redwood City 51
Wilmington 48
Rome 41
Buffalo 39
Ho Chi Minh City 39
Hefei 38
Hanover 36
Houston 36
Bengaluru 33
Woodbridge 33
Helsinki 32
Lauterbourg 31
Tianjin 31
Hanoi 30
Moscow 29
Jakarta 26
Cambridge 25
Madrid 25
Guangzhou 24
Ann Arbor 23
Shanghai 22
Boston 20
Bologna 19
London 19
São Paulo 19
Vienna 19
Brooklyn 18
Chicago 17
Naples 17
Washington 17
Des Moines 15
Hangzhou 15
Taipei 15
Warsaw 15
Cangzhou 14
Dong Ket 14
Seoul 14
Abidjan 13
Bergamo 13
Fremont 13
Nanjing 13
Rochester 13
Santiago 13
Toronto 13
Hyderabad 12
Jeddah 12
Krakow 12
Messina 12
Montreal 12
Queens 12
Amsterdam 11
Boardman 11
Bogotá 11
Munich 11
Adachi 10
Barcelona 10
Berlin 10
Nuremberg 10
Atlanta 9
Cattolica 9
Columbus 9
Florence 9
Genoa 9
Wroclaw 9
Birmingham 8
Brescia 8
Changsha 8
Iowa City 8
Osaka 8
Reston 8
San Diego 8
Sunnyvale 8
Sydney 8
Baltimore 7
Bangkok 7
Brussels 7
Chennai 7
Da Nang 7
Denver 7
Marugame 7
Miami 7
Totale 4.424
Nome #
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera : a propensity-matched study 1.397
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms : an European Leukemia Net study 597
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 275
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia : a report from the MPN subcommittee of the chronic malignancies working party of the European group for blood and marrow transplantation 262
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 257
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 257
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 247
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients 241
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 238
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea 225
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 220
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts 207
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT 200
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 198
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 197
Busulfan or thiotepa based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group 197
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 197
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients 179
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy 169
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms 169
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience 162
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis 160
Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival 160
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis 146
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation 137
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy 134
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists 133
Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study 132
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma 132
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 115
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer 112
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation 105
Detection of driver and subclonal mutations in myelofibrosis : clinical impact on pharmacologic and transplant based treatment strategies 104
Front-line therapy in polycythemia vera and essential thrombocythemia 69
Totale 7.730
Categoria #
all - tutte 18.537
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.537


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022672 74 41 67 53 58 34 37 41 81 67 39 80
2022/2023678 57 51 64 58 64 100 22 60 92 22 53 35
2023/20241.378 38 63 47 57 118 49 187 180 97 152 204 186
2024/20251.685 170 200 164 149 109 93 85 95 88 188 115 229
2025/20262.239 200 225 184 166 213 132 244 87 203 141 244 200
2026/2027104 104 0 0 0 0 0 0 0 0 0 0 0
Totale 7.730